Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3 tubes of Ameluz® over ...

Companies who run their early-stage clinical development outside the U.S. would “experience higher fees” according to an FDA ...

JANX007 shows significant PSA reductions and favorable rPFS in mCRPC patients, with a manageable safety profile. The trial identifies 6 mg and 9 mg as optimal doses, balancing safety and efficacy.

FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, an in situ ...

The clinical-stage biopharmaceutical company announced that its experimental drug, when combined with pembrolizumab, showed encouraging anti-tumor activity in patients with advanced solid tumors who ...

ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced today that ...

Trontinemab, utilizing Roche’s Brainshuttle technology, boosts drug delivery across the blood-brain barrier, driving robust ...

Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug ...

The donation will establish the Harold B. Smith Family Cancer Research Center at Rush within the Rush MD Anderson Cancer Center.

Protara Therapeutics shows promise with strong TARA-002 results and a solid cash runway. Click here to read my latest ...

Discover Kodiak's focused pipeline and late-stage trials advancing retinal disease therapies. Learn why KOD stands out in ...

Bayer (BAYRY) announced initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block ...